See the best free content plan templates to keep content production organized whether you're doing it yourself or managing a team. Content plan templates make it possible to track content ideas ...

The repository layout is pretty straightforward, including the CMake files to build the project, a conanfile where are declared examples of dependencies, a suppression list for cppcheck and the C++ ...

Aspire to reach new heights with a degree that equips you to be successful in a rapidly expanding field! The School of Nursing and Allied Health gives students the tools they need to pursue their ...

According to Reuters, the company earned $6.7 billion in revenue from Spikevax in 2023. Moderna has stated in the past that it is “not aware of any significant intellectual property impediments ...

According to the lawsuit, the development of Moderna’s COVID-19 vaccine, Spikevax, depended on key technological advancements made at Northwestern. Also Read: Alnylam’s Concedes Its Patent ...

The lawsuit said, opens new tab Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger RNA into the human body.

Moderna earned US$6.7 billion (S$8.7 billion) in revenue from Spikevax last year. Pfizer made US$11.2 billion from sales of Comirnaty, the Covid vaccine it developed with German partner BioNTech.

GlaxoSmithKline has filed lawsuits against Moderna in the U.S., claiming infringement on its mRNA technology patents with Moderna's COVID-19 vaccine, Spikevax. The legal action, part of a broader web ...

GlaxoSmithKline (GSK) has filed a patent infringement lawsuit against Moderna in Delaware, accusing the company of using its patented mRNA technology in their Spikevax COVID-19 vaccine without ...

Moderna earned $6.7 billion in revenue from Spikevax last year. Pfizer made $11.2 billion from sales of its and BioNTech's vaccine Comirnaty. Sales of both vaccines declined significantly last ...

The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and respiratory syncytial virus shot mResvia. The lawsuits, filed separately in the U.S.

The suits allege that nanoparticles used in Moderna's Spikevax COVID-19 vaccine and recently approved mRESVIA (mRNA-1345) vaccine for RSV – which competes with GSK's $1.7 billion blockbuster RSV ...